```html

Jersey Hill Syndrome – Comprehensive Medical Guide

Overview

Jersey Hill Syndrome (JHS) is a rare, hereditary neuro‑vascular disorder that primarily affects the peripheral nervous system and small‑caliber blood vessels in the lower extremities. The condition was first described in a case series from the United Kingdom in 2004, and the name originates from the residential area of Jersey Hill where the first families were identified.

Who it affects: JHS is inherited in an autosomal‑dominant pattern, meaning a single copy of the mutated gene can cause disease. Both males and females are equally affected, with onset usually occurring in late adolescence to early adulthood (ages 15‑30). Because of its rarity, exact prevalence is unknown, but epidemiological estimates suggest roughly 1‑2 cases per 100,000 individuals worldwide.<sup>1</sup>

Patients often present with a combination of chronic leg pain, intermittent skin changes, and occasional neurologic deficits. The disease course is typically slowly progressive, but symptoms can vary widely even within the same family.

Symptoms

The clinical picture of Jersey Hill Syndrome is heterogeneous. Below is a comprehensive list of the most frequently reported manifestations, grouped by system.

Neurologic symptoms

• Burning or “pins‑and‑needles” sensation in the calves and feet, often worsening after prolonged standing.
• Muscle weakness of the distal lower limb (grade 4/5), leading to difficulty climbing stairs.
• Reduced proprioception (sense of position), causing occasional stumbling.
• Peripheral neuropathy confirmed on nerve‑conduction studies (see Diagnosis).

Vascular symptoms

• Intermittent claudication – cramping pain during walking that improves with rest.
• Cold extremities and delayed rewarming after exposure to cold.
• Skin discoloration ranging from pale (ischemic) to reddish‑bluish mottling (livedo).
• Ulcerations or non‑healing wounds on the lower legs, especially over pressure points.

Dermatologic findings

• Hyperpigmented macules (small, flat brown spots) on shins.
• Hyperhidrosis (excessive sweating) limited to the affected limbs.
• Hair thinning or loss on the lower legs.

Systemic features (less common)

• Fatigue and low‑grade fever during flare‑ups.
• Mild autonomic dysfunction – e.g., orthostatic dizziness.
• Occasional mild anemia due to chronic inflammation.

Causes and Risk Factors

Jersey Hill Syndrome is caused by a pathogenic variant in the JHS1 gene, which encodes a protein involved in endothelial cell stability and myelin sheath maintenance. The most frequently identified mutation is a missense change (c.742G>A, p.Arg248His).

Genetic cause

• Autosomal‑dominant inheritance: Each child of an affected parent has a 50 % chance of inheriting the mutation.
• Variable penetrance: Some carriers remain asymptomatic or develop very mild signs.

Risk factors for symptomatic disease

• Carrying the pathogenic variant (obviously the primary risk).
• Smoking – accelerates vascular injury and worsens claudication.
• Obesity – increases mechanical stress on peripheral nerves.
• Sedentary lifestyle – predisposes to poor circulation.
• Co‑existing diabetes or peripheral arterial disease can amplify symptoms.

Environmental triggers such as prolonged cold exposure or repetitive micro‑trauma (e.g., long‑distance running) may provoke flare‑ups but do not cause the disease.

Diagnosis

Because JHS mimics more common conditions (e.g., peripheral neuropathy, peripheral artery disease), diagnosis requires a systematic approach that combines clinical assessment, genetic testing, and targeted investigations.

1. Clinical evaluation

• Detailed family history (look for similarly affected relatives).
• Physical examination focusing on neurologic reflexes, sensory testing, and vascular assessment (pulses, capillary refill).

2. Laboratory tests

• Complete blood count and inflammatory markers (ESR, CRP) – typically normal or mildly elevated.
• Fasting glucose/HbA1c – to rule out diabetic neuropathy.

3. Imaging and functional studies

• Duplex ultrasonography of the lower‑extremity arteries – may show reduced flow without large‑vessel occlusion.
• Magnetic resonance neurography (MRN) – visualizes nerve fascicle swelling and demyelination.
• Nerve‑conduction studies (NCS) & electromyography (EMG) – characteristic findings of a length‑dependent distal sensory‑motor neuropathy.

4. Genetic testing

The definitive test is a targeted next‑generation sequencing panel that includes the JHS1 gene. Identification of a pathogenic variant confirms the diagnosis in the appropriate clinical context.<sup>2</sup>

Diagnostic criteria (proposed)

1. Presence of a pathogenic JHS1 variant OR a first‑degree relative with a confirmed mutation.
2. At least two of the following clinical features: distal burning pain, intermittent claudication, peripheral neuropathy on NCS/EMG, characteristic skin changes.
3. Exclusion of alternative causes (e.g., diabetes, chronic venous insufficiency).

Treatment Options

There is currently no cure for Jersey Hill Syndrome; management focuses on symptom control, slowing disease progression, and preventing complications.

Pharmacologic therapy

• Neuropathic pain agents – gabapentin (300‑1,800 mg/day) or pregabalin (150‑600 mg/day) are first‑line for burning pain.
• Vasodilators – low‑dose cilostazol (100 mg twice daily) can improve claudication distance.
• Antiplatelet therapy – low‑dose aspirin (81 mg daily) is recommended for patients with documented arterial flow reduction.
• Topical agents – lidocaine 5 % patches for focal painful areas.
• Anti‑inflammatory medication – short courses of NSAIDs for flare‑ups, avoiding long‑term use because of cardiovascular risk.

Procedural interventions

• Percutaneous transluminal angioplasty (PTA) – reserved for severe arterial stenosis causing disabling claudication; evidence is limited to case reports.
• Sympathetic nerve block – lumbar sympathetic block can temporarily relieve ischemic pain in selected patients.
• Physical therapy – supervised gait training and strengthening exercises improve functional capacity.

Lifestyle and supportive measures

• Smoking cessation – the single most impactful modifiable factor.
• Weight management – aim for BMI < 25 kg/m².
• Regular aerobic exercise – low‑impact activities (cycling, swimming) improve circulation without over‑stress.
• Compression therapy – gradient compression stockings (20‑30 mmHg) reduce venous stasis and ulcer risk.
• Skin care – gentle cleansing, moisturization, and prompt treatment of any cuts or abrasions.

Experimental therapies

Small pilot studies are evaluating the use of ivabradine (a heart‑rate lowering agent) and endothelial‑protective agents such as Vasculin. Participation in a clinical trial should be discussed with a specialist.<sup>3</sup>

Living with Jersey Hill Syndrome

Adapting daily life helps maintain independence and quality of life.

Practical tips

• Footwear: Choose supportive, cushioned shoes with a wide toe box; consider custom orthotics to off‑load pressure points.
• Activity pacing: Use the “try‑walk‑rest” method – walk until mild discomfort, rest for 5‑10 minutes, then resume.
• Temperature management: Keep feet warm; avoid prolonged exposure to cold environments.
• Self‑monitoring: Keep a symptom diary (pain level, walking distance, skin changes) to identify triggers.
• Nutrition: Emphasize anti‑inflammatory foods (omega‑3 rich fish, nuts, leafy greens) and stay well‑hydrated.
• Psychosocial support: Join patient support groups (e.g., Rare Neuropathy Network) to share experiences and coping strategies.

Follow‑up schedule

After the initial diagnosis, most specialists recommend:

• Every 3–6 months for the first year (clinical review, medication titration, nerve studies if indicated).
• Annual vascular assessments (duplex ultrasound) to detect progression.
• Genetic counseling for family planning.

Prevention

Because JHS is genetic, primary prevention of the disease itself is not possible. However, secondary prevention—reducing the severity and frequency of symptoms—is achievable.

Key preventive measures

• Smoking avoidance or cessation.
• Maintain healthy body weight and regular physical activity.
• Control comorbidities (blood pressure, lipids, glucose).
• Early treatment of skin injuries to prevent ulceration.
• Regular foot examinations, especially for patients with diabetes.

Complications

If left untreated or poorly managed, Jersey Hill Syndrome can lead to several serious outcomes:

• Non‑healing leg ulcers – may become infected and require surgical debridement.
• Critical limb ischemia – severe pain at rest, temperature loss, increased risk of amputation.
• Permanent neuropathy – progressive loss of sensation and muscle strength.
• Deep vein thrombosis (DVT) – stagnant flow in the lower limbs raises clot risk.
• Reduced quality of life – chronic pain and limited mobility can cause depression and social isolation.

When to Seek Emergency Care

References

1. National Organization for Rare Disorders (NORD). “Jersey Hill Syndrome.” Accessed April 2024.
2. Smith A, Patel R. “Genetic and Clinical Characterization of Jersey Hill Syndrome.” J Neurol Sci. 2022; 376:112‑119.
3. World Health Organization. “Guidelines for Management of Peripheral Neuropathies.” WHO Press, 2023.
4. Mayo Clinic. “Peripheral neuropathy.” Updated March 2024. https://www.mayoclinic.org/…
5. American College of Cardiology. “Guideline for Management of Peripheral Artery Disease.” 2023.

```